A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis

Expert Opinion on Drug Safety

Volumn 14, Issue 12, 2015, Pages 1961-1967

  Wulffraat, Nico M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

auto inflammatory syndromes; IL 1 family; inflammasome; registry; safety; systemic onset juvenile idiopathic arthritis

Indexed keywords

CANAKINUMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; GASTROENTERITIS; GENE MUTATION; HUMAN; INFECTION; INJECTION SITE REACTION; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS PROTEINOSIS; NEUTROPENIA; PHARYNGITIS; PNEUMONIA; PULMONARY HYPERTENSION; REVIEW; RHINITIS; RHINOPHARYNGITIS; SINUSITIS; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; THROMBOCYTOPENIA; TONSILLITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, JUVENILE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; IMMUNOLOGY; PATHOPHYSIOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; CLINICAL TRIALS AS TOPIC; HUMANS; INTERLEUKIN-1;

EID: 84951906898     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2016.1112377     Document Type: Review

References (48)

1. Auron PE, Webb AC, Rosenwasser LJ, et al. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci U S A. 1984;81 (24):7907-7911
2. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013;39(6):1003-1018
3. Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: A clinical perspective. Cell. 2010;140(6):784-790
4. van de Veerdonk FL, Netea MG, Dinarello CA, et al. Inflammasome activation and IL-1beta and IL-18 processing during infection. Trends Immunol. 2011;32 (3):110-116
5. Palomo J, Dietrich D, Martin P, et al. The interleukin (IL)-1 cytokine family-balance between agonists and antagonists in inflammatory diseases. Cytokine. 2015;76 (1):25-37
6. Dinarello CA, Novick D, Kim S, et al. Interleukin-18 and IL-18 binding protein. Front Immunol. 2013;4:289
7. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87(6):2095-2147
8. Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1receptor antagonist. N Engl J Med. 2009;360 (23):2426-2437
9. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117(14):3720-3732
10. Karmakar M, Katsnelson M, Malak HA, et al. Neutrophil IL-1beta processing induced by pneumolysin is mediated by the NLRP3/ASC inflammasome and caspase-1 activation and is dependent on K+ efflux. J Immunol. 2015;194(4):1763-1775
11. Rijneveld AW, Florquin S, Speelman P, et al. Interleukin-1 receptor antagonist transiently impairs antibacterial defense but not survival in murine pneumococcal pneumonia. Eur Cytokine Netw. 2003;14 (4):242-245
12. Dinarello CA. An expanding role for interleukin-1 blockade from gout to cancer. Mol Med. 2014;20(Suppl. 1):S43-S58
13. Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;25 (6):469-484
14. Bakker AC, Joosten LA, Arntz OJ, et al. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum. 1997;40(5):893-900
15. Loet L, Nordstrom D, Rodriguez M, et al. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA trial. J Rheumatol. 2008;35(8):1538-1544
16. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol. 2002;2(5):364-371
17. Frenkel J, Wulffraat NM, Kuis W. Anakinra in mutation-negative NOMID/CINCA syndrome: comment on the articles by Hawkins et al and Hoffman and Patel. Arthritis Rheum. 2004;50 (11):3738-3739
18. Hawkins PN, Lachmann HJ, Aganna E, et al. Spectrum of clinical features in muckle-wells syndrome and response to anakinra. Arthritis Rheum. 2004;50 (2):607-612
19. Grom AA. Canakinumab for the treatment of systemic juvenile idiopathic arthritis. Expert Rev Clin Immunol. 2014;10(11):1427-1435
20. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396-2406
21. Ruperto N, Quartier P, Wulffraat N, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64(2):557-567
22. Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis: A revolution in care. Pediatr Rheumatol Online J. 2014;12:13
23. Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol. 2014;66(6):1405-1413
24. Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63(2):545-555
25. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-Associated periodic syndrome. N Engl J Med. 2009;360 (23):2416-2425
26. Kuemmerle-Deschner JB, Hachulla E, Cartwright R, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrinassociated periodic syndrome across different severity phenotypes. Ann Rheum Dis. 2011;70(12):2095-2102
27. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63(4):465-482
28. Frosch M, Roth J. New insights in systemic juvenile idiopathic arthritis-from pathophysiology to treatment. Rheumatology (Oxford). 2008;47(2):121-125
29. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377 (9783):2138-2149
30. Holzinger D, Kessel C, Omenetti A, et al. From bench to bedside and back again: translational research in autoinflammation. Nat Rev Rheumatol. 2015;11(10):573-585
31. Kimura Y, Weiss JE, Haroldson KL, et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2013;65(5):745-752
32. Davi S, Minoia F, Pistorio A, et al. Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66(10):2871-2880
33. Cron RQ, Davi S, Minoia F, et al. Clinical features and correct diagnosis of macrophage activation syndrome. Expert Rev Clin Immunol. 2015;16:1-11
34. Novartis Pharmaceuticals Corp [Internet]. ILARIS, prescribing information. 2013 [cited 2013 Sep 4]. Avialbe from: http://www.hcp.ilaris.com/c/sjia
35. Church LD, McDermott MF. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther. 2009;11(1):81-89
36. Lequerre T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset still disease: preliminary experience in France. Ann Rheum Dis. 2008;67(3):302-308
37. Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70(5):747-754
38. Gattorno M, Piccini A, Lasiglie D, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008;58(5):1505-1515
39. Vastert SJ, de Jager W, Noordman BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 2014;66 (4):1034-1043
40. Kafka D, Ling E, Feldman G, et al. Contribution of IL-1 to resistance to streptococcus pneumoniae infection. Int Immunol. 2008;20(9):1139-1146
41. Grom AA, Ilowite NT, Pascual V, et al. Canakinumab in systemic juvenile idiopathic arthritis: impact on the rate and clinical presentation of macrophage activation syndrome. Arthritis Rheumatol. 2015;Aug 28. doi:10.1002/art.39407
42. Diak P, Siegel J, La GL, et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 2010;62 (8):2517-2524
43. Swart JF, De RS, Wulffraat NM. What are the immunological consequences of longterm use of biological therapies for juvenile idiopathic arthritis? Arthritis Res Ther. 2013;15(3):213
44. Beukelman T, Haynes K, Curtis JR, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64 (4):1263-1271
45. Pham T, Bachelez H, Berthelot JM, et al. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine. 2011;78 (Suppl 1):15-185
46. Brunner H, Lomax KG, Levy S. Half-life and safety of canakinumab in pediatric patients: comment on the article by Ilowite et al. Arthritis Rheumatol. 2015;67 (3):857-858
47. Taylor GJ, Wainwright P. Open label extension studies: research or marketing? Bmj. 2005;331(7516):572-574
48. EU Medicines Agencies Network Strategy to 2020 [Internet]. 2015 [cited 2015 Mar 27]. Ref Type: Internet Communication. Available from: http://www.ema.europa.eu/ema/.